Microspectroscopy, the marriage of spectroscopic chemical identification with microscopic spatial resolution, has advanced from Perkin-Elmer's first commercial infrared microspectrometer in 1953 to today's nanoscale AFM-IR probes, synchrotron-brightness infrared beamlines, and compact hyperspectral tissue imaging devices being developed for AI-assisted cancer detection.
Microspectroscopy, the marriage of spectroscopic chemical identification with microscopic spatial resolution, has advanced from Perkin-Elmer's first commercial infrared microspectrometer in 1953 to today's nanoscale AFM-IR probes, synchrotron-brightness infrared beamlines, and compact hyperspectral tissue imaging devices being developed for AI-assisted cancer detection.
Continued refinement of atomic force microscopy-infrared (AFM-IR) techniques is pushing chemical imaging resolution from micrometers toward single-digit nanometers, while new patents in hyperspectral video acquisition extend spectral measurement to moving samples.
This article traces microspectroscopy's technical evolution and current frontiers, featuring perspectives from researchers developing next-generation chemical imaging systems for biomedical and materials applications.
Microspectroscopy combines two historically separate analytical capabilities, spectroscopic chemical identification and microscopic spatial resolution, into a single measurement that reveals not just what a sample contains, but precisely where within the sample each component is located. Commercial infrared microspectroscopy dates to 1953, when Perkin-Elmer introduced its Model 85 infrared microspectrometer, though the field remained a niche curiosity until Vincent J. Coates of Nanometrics revived interest with the NanoSpec/20 IR microspectrometer in 1978 and the subsequent commercial adoption of Fourier-transform infrared spectrometers after 1983 catalyzed rapid growth.1
For most of its history, infrared microspectroscopy's spatial resolution remained fundamentally constrained by diffraction, limiting practical chemical imaging to spot sizes on the order of ten micrometers or larger. That constraint has eroded dramatically over the past 15 years. Atomic force microscopy-infrared (AFM-IR) spectroscopy, first demonstrated by Alexandre Dazzi and colleagues at the Université Paris-Sud in 2005,2 and later commercialized as the nanoIR system by Anasys Instruments, where Craig Prater and Kevin Kjoller led its further development, improved resolving power from roughly 10 micrometers to approximately 10 nanometers, a three-order-of-magnitude leap achieved by using an atomic force microscope tip, rather than a focused light spot, to sense localized photothermal expansion.1
This article surveys the technologies extending microspectroscopy's reach today, from synchrotron-brightness infrared beamlines to patented hyperspectral video acquisition methods and compact tissue imaging devices being developed for AI-assisted diagnosis, drawing on recent literature, patents, and researcher commentary.
AFM-IR's central innovation, using a scanning probe tip rather than a focused infrared beam to sense sample absorption, decouples spatial resolution entirely from the infrared diffraction limit, since resolution is instead set by the mechanical contact area of the AFM tip. This capability has proven especially valuable in polymer science, pharmaceutical materials characterization, and semiconductor failure analysis, where chemical heterogeneity often occurs at length scales far below what conventional FT-IR microscopy can resolve.
A related but distinct approach, optical photothermal infrared (O-PTIR) microscopy commercialized as the mIRage system by Photothermal Spectroscopy Corp., uses a visible-wavelength probe laser rather than a mechanical AFM tip to sense infrared-induced photothermal expansion, achieving approximately 450-nanometer resolving power in noncontact reflection mode.1,3 While AFM-IR delivers superior spatial resolution through direct mechanical contact, O-PTIR's noncontact operation substantially simplifies sample preparation, illustrating how the two photothermal techniques occupy complementary niches within the broader microspectroscopy toolkit rather than directly competing on a single performance axis.
Quantum cascade (QC) lasers, the subject of a 1994 patent application by Federico Capasso, Alfred Y. Cho, Jerome Faist, and colleagues at Bell Laboratories, have become a critical enabling technology for high-speed microspectroscopic imaging. Tunable across the mid-infrared fingerprint region, with high output intensity, QC lasers allow spectral mapping systems to acquire chemical images at individual diagnostic wavelengths at speeds that broadband thermal-source FT-IR microscopy cannot match, since only the wavenumbers relevant to a given application need to be measured rather than a complete interferogram at every pixel.1 This discrete-frequency imaging approach, discussed in greater depth in this series' companion article on FT-IR spectroscopy, has become foundational to commercial laser direct infrared (LDIR) chemical imaging platforms used in microplastics and pharmaceutical microspectroscopy applications.
For applications demanding both high spatial resolution and high signal-to-noise on weakly absorbing or highly localized samples, synchrotron facilities provide infrared brightness orders of magnitude beyond conventional thermal sources. Synchrotron-based FT-IR microspectroscopy has been applied at the MIRAS beamline of Spain's ALBA Synchrotron to operando characterization of metal-ion organic battery materials during active charge-discharge cycling, allowing researchers to track chemical changes in electrode materials under real operating conditions rather than in post-mortem analysis.4 Beamlines dedicated to infrared spectromicroscopy, such as the MIRIAM (B22) beamline at the UK's Diamond Light Source, continue to support biomedical applications ranging from metabolic imaging of single living cells to chemical mapping of tissues and other complex materials, applications that benefit directly from the combination of high spatial resolution and the high infrared flux that only synchrotron sources can practically provide.5
Hyperspectral imaging, which captures a full spectrum at every image pixel across visible, near-infrared, and sometimes ultraviolet wavelengths, is advancing rapidly toward clinical and point-of-care applications.6,7 Dr. Baowei Fei, professor of bioengineering and director of the Center for Imaging and Surgical Innovation at the University of Texas at Dallas, has developed a prototype LED-based hyperspectral micro-imaging device small enough to be paired with an endoscope, intended for real-time cancer detection during medical procedures. The device has been tested on tissue samples but is not yet approved for use in patients.8
“With hyperspectral imaging, we can add potentially hundreds of narrow wavelengths of light to reveal subtle differences in tissue in real-time that a standard camera cannot detect. Different types of tissue have unique spectral signatures that potentially can help physicians detect cancer cells more accurately.”
— Dr. Baowei Fei, Professor of Bioengineering and Director, Center for Imaging and Surgical Innovation, University of Texas at Dallas
Fei further described a longer-term goal of pairing the technology with cloud-based artificial intelligence for remote triage and diagnostic support.8
“Basically, you could complete the scan, and the information would be wirelessly transferred to the cloud. Then, AI may determine the lesion is suspicious and refer the person to a medical center for follow-up. Our goal is to produce imaging systems that are really affordable as well as cost-effective, meaning they could find cancers at earlier stages and reduce the need for unnecessary tissue removal and testing.”
— Dr. Baowei Fei, University of Texas at Dallas
Beyond static hyperspectral image capture, a September 2025 U.S. patent granted to CytoViva Inc. addresses one of dynamic biological microspectroscopy's most persistent challenges: measuring spectra from samples that are moving. Invented by James Melvin Beach, James Lawrence Uertz, Andrew Liu, Byron J. Cheatham, and Samuel M. Lawrence, the patent describes a system that simultaneously captures optical images and hyperspectral data, compiling them into a time-stamped, navigable video sequence that allows researchers to identify frames where a moving sample element, such as a nanoscale exosome or a stem cell, aligns with the spectrograph's imaging slit and extract a spectral profile at that precise moment.9 Applications highlighted in the patent include label-free identification of nanoscale biological particles for therapeutic development, a task that traditionally required immobilizing samples on a slide, potentially altering the very biological behavior researchers seek to characterize.
Beyond biomedicine, hyperspectral darkfield microscopy has become a standard tool for label-free nanoparticle characterization in environmental toxicology and nanomaterials research.10,11 Instruments capable of resolving individual nanoparticles by their characteristic scattering spectra, without the fluorescent tagging required by many optical microscopy techniques, allow researchers to track engineered nanoparticles in complex biological or environmental matrices, distinguishing, for instance, silver nanoparticles from the natural background of wetland or wastewater samples based on their spectral signatures.10 This label-free capability is particularly valuable in nanotoxicology studies, where nanoparticles can be located within cells and tissues in their unmodified state, without labeling steps that could perturb the system under study.11
Microspectroscopy's seven-decade evolution, from Perkin-Elmer's first commercial infrared microspectrometer to today's nanoscale AFM-IR probes and compact hyperspectral clinical imaging devices, illustrates a consistent pattern: each major advance has come from re-engineering how spatial and spectral information are jointly acquired, rather than from incremental improvement to a single fixed measurement architecture. AFM-IR decoupled resolution from the infrared diffraction limit entirely by substituting a mechanical probe for a focused light spot; quantum cascade lasers decoupled acquisition speed from broadband interferometric scanning; and synchrotron sources decoupled achievable signal-to-noise from the physical limitations of thermal infrared emitters.
The most recent advances, exemplified by CytoViva's patented hyperspectral video approach and Baowei Fei's LED-based clinical hyperspectral imaging system, extend this pattern into the temporal and computational domains, capturing spectral information from moving, living samples and, in Fei's case, aiming to pair it with cloud-based artificial intelligence for remote interpretation.
Taken together, these advances show microspectroscopy maturing along two complementary axes simultaneously: ever-finer spatial resolution at the nanoscale for materials and single-cell research, and ever-broader, faster, AI-assisted acquisition for clinical and point-of-care deployment.
Continued convergence between microspectroscopy modalities is likely: expect closer integration of AFM-IR's nanoscale spatial resolution with quantum cascade laser acquisition speed, and further blending of hyperspectral imaging with AI-based classification models trained on increasingly large clinical and materials-science spectral datasets. As Dr. Fei's envisioned cloud-connected diagnostic workflow illustrates, the next phase of hyperspectral microscopy adoption in medicine will likely depend as much on affordable hardware and AI triage infrastructure as on further gains in raw spectral or spatial resolution.
Synchrotron infrared microspectroscopy will likely remain the gold standard for the most demanding operando and single-cell applications, even as increasingly capable benchtop and portable instruments absorb a growing share of routine microspectroscopic analysis. Meanwhile, patents such as CytoViva's hyperspectral video acquisition method point toward a broader trend of extending microspectroscopy from static, immobilized samples toward dynamic, living systems, a shift with significant implications for cell therapy manufacturing, exosome-based diagnostics, and live-cell pharmacology research.
(1) Reffner, J. A. Advances in Infrared Microspectroscopy and Mapping Molecular Chemical Composition at Submicrometer Spatial Resolution. Spectroscopy 2018, 33 (9).
(2) Dazzi, A.; Prazeres, R.; Glotin, F.; Ortega, J. M. Local Infrared Microspectroscopy with Subwavelength Spatial Resolution with an Atomic Force Microscope Tip Used as a Photothermal Sensor. Opt. Lett. 2005, 30 (18), 2388–2390. DOI:
(3) Prater, C.; Cheng, J.-X.; Kansiz, M. An Introduction to Optical Photothermal Infrared (O-PTIR) Spectroscopy. Spectroscopy Online, September 22, 2025.
(4) Black, A. P.; Tchitchekova, D. S.; Patil, N.; Goujon, N.; Mecerreyes, D.; Marcilla, R.; Yousef, I.; Ponrouch, A. Operando Synchrotron-Based Fourier Transform Infrared Microspectroscopy of Metal-Ion Organic Battery Materials. Chem. Mater. 2026, 38 (2), 645–656. DOI:
(5) Cinque, G.; Frogley, M. D.; Wehbe, K.; Nguyen, T.-N. Q.; Fitzpatrick, A.; Kelley, C. S. Synchrotron-Based Infrared Spectral Imaging at the MIRIAM Beamline of Diamond Light Source. Synchrotron Radiat. News 2017, 30 (4), 11–16. DOI:
(6) He, Y.; Zhao, Y.; Xu, J.; et al. Hyperspectral Imaging for Benign and Malignant Diagnosis of Breast Tumors. J. Biophotonics 2025, 18 (10), e202500188. DOI:
(7) Composto, A.; Privitera, L.; Riva, M.; et al. Hyperspectral Imaging for Tumor Resection Guidance in Surgery: A Systematic Review of Preclinical and Clinical Studies. J. Biomed. Opt. 2025, 30 (S2), S23909. DOI:
(8) Horner, K. Researchers Develop New Imaging Tool for Earlier Cancer Detection. UT Dallas News Center, September 17, 2025.
(9) Beach, J. M.; Uertz, J. L.; Liu, A.; Cheatham, B. J.; Lawrence, S. M. Hyperspectral Imaging of Moving Microscopic Sample Elements. U.S. Patent 12,429,376 B2, September 30, 2025 (assignee: CytoViva Inc.).
(10) Badireddy, A. R.; Wiesner, M. R.; Liu, J. Detection, Characterization, and Abundance of Engineered Nanoparticles in Complex Waters by Hyperspectral Imagery with Enhanced Darkfield Microscopy. Environ. Sci. Technol. 2012, 46 (18), 10081–10088. DOI:
(11) Roth, G. A.; Tahiliani, S.; Neu-Baker, N. M.; Brenner, S. A. Hyperspectral Microscopy as an Analytical Tool for Nanomaterials. Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2015, 7 (4), 565–579. DOI:
